Cover
Cover | Feb. 04, 2021 |
Cover [Abstract] | |
Document Type | 8-K/A |
Amendment Flag | true |
Amendment Description | This Current Report on Form 8-K/A is being filed as an amendment (this “Amendment No. 1”) to the Current Report on Form 8-K filed by Ironwood Pharmaceuticals, Inc. (the “Company”) with the Securities and Exchange Commission on February 8, 2021 (the “Original Report”). In the Original Report, the Company disclosed that, among other events, Mark Mallon resigned as Chief Executive Officer of the Company and Thomas McCourt, the Company’s President, will become the Company’s interim Chief Executive Officer in addition to his role as President, in each case, effective March 12, 2021. This Amendment No. 1 is being filed to provide a description of certain compensation arrangements approved by the board of directors of the Company (the “Board’) on March 10, 2021 in connection with Mr. McCourt’s appointment as interim Chief Executive Officer. Except as set forth herein, this Amendment No. 1 does not amend, modify or update the disclosure contained in the Original Report. |
Document Period End Date | Feb. 4, 2021 |
Entity File Number | 001-34620 |
Entity Registrant Name | IRONWOOD PHARMACEUTICALS, INC. |
Entity Central Index Key | 0001446847 |
Entity Tax Identification Number | 04-3404176 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 100 Summer Street |
Entity Address, Address Line Two | Suite 2300 |
Entity Address, City or Town | Boston |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02110 |
City Area Code | 617 |
Local Phone Number | 621-7722 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Class A common stock, $0.001 par value |
Trading Symbol | IRWD |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |